Search the GHTC website

Global health R&D delivers for Virginia

US government investment in global health R&D has delivered

$874.5 million
to Virginia research institutions
9,700+ new jobs
for Virginia
Global health R&D at work in Virginia

Many drugs used to treat HIV/AIDS have life-threatening side effects. One new, highly effective drug doesn’t, but it’s extremely expensive to produce. Virginia Commonwealth University is aiming to make it cheaper. Drugs with fewer side effects are important for long-term care of HIV/AIDS patients, who must take the drugs for life. The university has a proven track record for reinventing how drugs are made, resulting in cost-effective products that save lives.

  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: PATH/Minzayar